Amantadine
- PDF / 169,556 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 64 Downloads / 146 Views
1 S
Various toxicities: 3 case reports In a retrospective, single-centre study of 30 patients began in January 2013, 3 patients [ages and sexes not stated] were described, who developed confusion, hallucinations, leg oedema or excessive sleepiness during treatment with amantadine for advanced parkinsonism. All the patients had a history of advanced parkinsonism, for which they started receiving IV amantadine infusion at a loading dose of 200/400mg per day for 5 days followed by a maintenance dose of 200/400mg once every 1–3 weeks. IV amantadine strength was 200 mg/500mL. In-between of IV amantadine infusion, the patients received oral amantadine 200mg per day (received on those days when the patients were not treated with IV amantadine). During the therapy, the patients developed confusion and hallucinations (1 patient), leg oedema (1 patient), and excessive sleepiness (1 patient) [duration of treatment to reactions onsets not stated]. Despite these side effects, none of the patients was dropped out from the study [outcomes not stated]. Kestenbaum M, et al. Repeated Intravenous Amantadine Infusions in Advanced Parkinsonism: Experience of a Large Movement Disorder Center. Israel Medical Association 803445939 Journal: Imaj 12: 812-816, No. 21, Dec 2019. Available from: URL: https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2019&month=12&page=812
0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 18 Jan 2020 No. 1787
Data Loading...
